European neurological review最新文献_第6页

Parkinson’s Disease Psychosis – Patterns of Care and Treatment in the EU-5 from Neurologists’ Perspective 帕金森氏病精神病-从神经科医生的角度看欧盟五国的护理和治疗模式

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.02.92

K. Cook, R. Suresh, K. Lou, J. Kesslak, D. Fredericks

{"title":"Parkinson’s Disease Psychosis – Patterns of Care and Treatment in the EU-5 from Neurologists’ Perspective","authors":"K. Cook, R. Suresh, K. Lou, J. Kesslak, D. Fredericks","doi":"10.17925/ENR.2017.12.02.92","DOIUrl":"https://doi.org/10.17925/ENR.2017.12.02.92","url":null,"abstract":"O ver half of patients with Parkinson’s disease (PD) develop symptoms of psychosis during the course of their disease. Existing guidelines include recommendations for managing symptoms of psychosis in patients with PD. However, the extent to which such recommendations translate to clinical practice in major European nations is unclear. The current study describes trends in the clinical management of patients diagnosed with PD psychosis (PDP) based on survey responses and patient chart reviews from 437 neurologists across France, Germany, Italy, Spain, and the UK (collectively, the EU-5). Surveyed neurologists reported that PDP typically manifests four or more years after the diagnosis of PD, with the most commonly reported initial symptoms being moderately disruptive visual hallucinations, agitation, and illusions/false sense of presence. PD medications adjustment was the most common first-line intervention, applicable to an estimated 59–79% of patients for the initial management of PDP depending on country. Responses from surveyed neurologists suggest PD medications adjustment is a temporary solution for many patients with PDP and that there is considerable variability in subsequent lines of intervention. The current report provides a resource for understanding the patterns of care and treatment for PDP across these major European nations.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"92"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A review of vascular disease risk factors and multiple sclerosis 血管疾病危险因素与多发性硬化的研究综述

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/USE.2017.13.02.90

M. Kannan, V. Yadav

引用次数: 0

Therapeutic use of the Arts for Patients with Multiple Sclerosis 艺术治疗在多发性硬化症患者中的应用

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/USN.2017.13.02.82

Lisa M. Gallagher, F. Bethoux

引用次数: 3

Drug Development in Alzheimer’s Disease—The Role of Default Mode Network Assessment in Phase II 阿尔茨海默病的药物开发-默认模式网络评估在II期中的作用

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/USE.2017.13.02.67

J. Cummings, K. Zhong, D. Cordes

引用次数: 8

Preventative Therapies for Migraine 偏头痛的预防性治疗

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.02.62

J. Rothrock

引用次数: 0

Osmophobia and Odour-triggered Headaches – Review of the Literature and Main Research Centres 嗅觉恐惧症和气味引发的头痛——文献综述和主要研究中心

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.01.24

R. Silva-Néto, A. Soares

{"title":"Osmophobia and Odour-triggered Headaches – Review of the Literature and Main Research Centres","authors":"R. Silva-Néto, A. Soares","doi":"10.17925/ENR.2017.12.01.24","DOIUrl":"https://doi.org/10.17925/ENR.2017.12.01.24","url":null,"abstract":"T here is an important relationship between odours and primary headaches. Patients may present osmophobia during headaches and odours may trigger headache attacks. This review aimed to describe the studies on osmophobia, odour-triggered headache, the main researchers and their research centres. Publications on the relationship between odours and primary headaches were searched in 193 sovereign countries and 48 dependent territories in all continents. We consulted the PubMed database and used the descriptors: “osmophobia in [name of the country or territory]”; “odours and headache in [name of the country or territory]” and “smell and headache in [name of the country or territory]”. A total of 254 articles were found, but only 31 articles were considered relevant and composed this review. Of the 31 articles, 90.3% were cross-sectional studies, 6.5% case reports and 3.2% systematic reviews. All studies were performed on three continents: Europe (45.2%), America (32.2%) and Asia (22.6%). For the purpose of this study, North America and South America have been classed as one continent. No research was developed in Africa or Australia. More than 50.0% of the studies were conducted in Italy and Brazil. Only five authors published 38.7% of the studies. Osmophobia during headache attacks was investigated in 67.7% of studies, and odour-triggered headache in 19.3%. Studies on osmophobia and/or odour-triggered headache were carried out in several countries. They were useful in differentiating between migraine and tension-type headache. This could improve the accuracy of diagnosis of migraine compared to the current criteria.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

New and Evolving Treatment Goals in Multiple Sclerosis – the Role of Teriflunomide 新的和不断发展的治疗目标在多发性硬化症-泰瑞氟米特的作用

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.01.37

P. Vermersch

引用次数: 0

Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis 阿仑单抗选择性靶向T和B细胞群治疗多发性硬化症

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.02.78

N. Grigoriadis

引用次数: 0

Advances in Multiple Sclerosis 多发性硬化的研究进展

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.01.13

I. Milonas

引用次数: 0

Alzheimer Europe Publication Highlights Inequalities in Access to Dementia Care and Treatment Across Europe 阿尔茨海默病欧洲出版物强调了在整个欧洲获得痴呆症护理和治疗方面的不平等

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.02.68

J. Georges

引用次数: 2